Virbac SA (0NM7)
London Exchange · UK · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 349.50 |
|---|---|
| 52-week range | 297.00 – 385.50 |
| Return, 1 month / 3 months | +13.3% / +0.1% |
| Return, 1 year / 3 years | −1.7% / +39.6% |
| Trend | Uptrend |
| RSI (14) | 78 |
| Volatility (1 year) | 24.4% |
| Worst drawdown (1 year) | -21.3% |
| Average daily value traded | 0.05M EUR |
| Dividend yield | 0.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Virbac is an animal health company that develops and makes medicines, vaccines and hygiene products for pets and farm animals. Its products serve veterinarians and livestock producers, covering companion animals such as dogs and cats as well as cattle, pigs and poultry. The company is based in France and operates internationally, with a product range that includes parasiticides, antibiotics, dermatological treatments and nutritional supplements for animals.
On this site Virbac SA appears as a stock on the London Exchange (UK), code 0NM7, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Virbac SA (0NM7) trades on the London Exchange in UK. It last closed at EUR 349.50 on 22 October 2026.
Its price-based Market X-Ray is 47 out of 100 (a weak price profile), ranking 2,253 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 1.7% and over the last three months it rose 0.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 51 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 2.1% | ||
| From 52-week high | -9.3% | ||
| Momentum | 39 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 0.1% | ||
| 6-month return | -7.6% | ||
| 12-month return, skipping the last month | -13.3% | ||
| Stability (higher is calmer) | 73 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 24.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -21.3% | ||
| Liquidity | 23 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.05M EUR | ||
| Zero-volume days | 21.7% | ||
| Income | 23 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.4% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +4.3% |
|---|---|
| 1 month | +13.3% |
| 3 months | +0.1% |
| 6 months | −7.6% |
| 1 year | −1.7% |
| 3 years | +39.6% |
| 5 years | −7.3% |
Signals
| 50-day / 200-day average | 320.60 / 342.25 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 8.62 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 2 Jul 2026 | EUR 1.4500 |
| 24 Jun 2025 | EUR 1.4500 |
| 25 Jun 2024 | EUR 1.3200 |
| 26 Jun 2023 | EUR 1.3200 |
| 24 Jun 2022 | EUR 1.2500 |
| 23 Jun 2021 | EUR 0.7500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.